Best Cardiac and Vascular Disorders Companies in New Jersey, United States
The 32 best Cardiac and Vascular Disorders companies in New Jersey, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Impulse Dynamics.
Ranked: Best Cardiac and Vascular Disorders companies in New Jersey
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Impulse Dynamics Provider of implantable device for treatment of chronic heart failure 40Funding top 13%Moat top 31%Product top 34%Tech top 49% All 10 signals ▾Fundingtop 13% Moattop 31% Producttop 34% Techtop 49% Patentsbottom 49% Globalbottom 46% Innovationbottom 45% Marketbottom 41% Growthbottom 38% Newsbottom 27% Funding: Raised $443M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 18 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $443M | 10 mo ago | Series F | 36 | — | 18 patents Patents concentrated in health & consumer products | — |
| 2 | CORXEL Developer of therapies for patients with cardiometabolic conditions | $287M | 9 mo ago | Series D | — | Sandy Mou CEO | — | — |
| 3 | Svelte Medical Systems Developer of drug eluting coronary stents | $133M | 66 mo ago | Deadpooled | 3 | Jack Darby President And Ceo | — | — |
| 4 | Intact Vascular Provider of implant for artery repair after angioplasty | $123M | 75 mo ago | Acqui-Hired | 64 | — | 174 patents Intravascular delivery and fixation devices for plaque stabilization and implant deployment | — |
| 5 | Vascular Therapies Biotechnology firm improving vascular access by reducing surgical stenosis | $104M | 56 mo ago | Series C | 9 | Samuel Liang President/CEO | 25 patents Drug‑eluting, resorbable vascular implants and closure devices for restenosis prevention | — |
| 6 | CircuLite Developer of cardiac implants for early-stage heart failure patients | $99M | 158 mo ago | Acqui-Hired | 13 | Paul Southworth CEO & President | 313 patents Implantable cardiovascular assist devices and vascular cannula connector technologies | — |
| 7 | KBP BioSciences Innovating therapies for unmet medical needs in hypertension, cardiorenal, and infectious diseases | $76M | 106 mo ago | Series A | 37 | — | — | — |
| 8 | TyRx Antibacterial envelopes for cardiac implants | $71M | 161 mo ago | Acquired | 42 | — | 134 patents Surgical hemostatic and anchorage polymer devices, including mesh prostheses and implant coatings. | — |
| 9 | Bellerophon Therapeutics Device for treatment of pulmonary hypertension | $46M | 108 mo ago | Public | 18 | — | — | — |
| 10 | Percutaneous Valve Technologies Catheter-based approach for heart valve replacement | $20M | 286 mo ago | Acquired | — | — | — | — |
| 11 | HDL Therapeutics Developer of therapy to reverse coronary atherosclerosis | $18M | 40 mo ago | Series B | 6 | — | — | — |
| 12 | Lisata Developer of therapeutics for cancer and vascular disorders | $15M | 75 mo ago | Acquired | 27 | — | — | — |
| 13 | Vasade Biosciences Developer of adenylyl cyclase inhibitors for the treatment of cardiovascular diseases | $6M | 47 mo ago | Deadpooled | — | Dorothy E Vatner Co-Founder & MD | — | — |
| 14 | FluoroPharma PET imaging agents for the detection of coronary artery disease, Alzheimer's and others. | $6M | 127 mo ago | Deadpooled | 4 | — | 9 patents Fluorinated small-molecule therapeutics for Alzheimer's disease detection and treatment | — |
| 15 | CorFigo Developer of a trans-pericardial tissue ablation device | $2M | 10 mo ago | Seed | 4 | Deron Siddons Co-Founder & CEO | 34 patents Cryogenic cooling and storage systems for medical tissue ablation devices | — |
| 16 | Amorcyte Stem cell therapeutics for cardiovascular disease. | $1M | 183 mo ago | Acqui-Hired | 1 | — | 51 patents Cardiovascular regenerative therapeutics for progressive myocardial injury due to vascular insufficiency | — |
| 17 | Circuport Implantable vascular access port for hemodialysis | $800K | 196 mo ago | Seed | 3 | John Edoga Co-Founder | 13 patents Patents concentrated in health & consumer products | — |
| 18 | VasoPrep Surgical Pre-surgical vein preparation kit for CABG | $790K | 155 mo ago | Deadpooled | — | Cynthia Lander Founder & CEO | — | — |
| 19 | Snowdon US-based, early-stage biopharma discovering and developing anti-thrombotics for CV disease | $500K | 191 mo ago | Deadpooled | 1 | William Welsh Co-Founder | — | — |
| 20 | Synsei Non-invasive device to measure fetal cardiology | $150K | 154 mo ago | Deadpooled | — | William Braunlin Co-Founder | — | — |
| 21 | VascuLogic Developing image-guided medical devices for improved venipuncture and diagnostics | $149K | 142 mo ago | Funding Raised | 4 | Tim Maguire Co-Founder | 4 patents Robotic, 3D NIR-guided automated vascular imaging and needle puncture systems | — |
Top 12 Cardiac and Vascular Disorders companies in New Jersey
#1
Series F · Marlton, New Jersey · founded 1998 · 36 employees$443.1Mraised▾
Impulse Dynamics is focussed on developing solutions for the treatment of Chronic Heart Failure. They have developed, Optimizer IV, a minimally invasive implantable device based on novel Cardiac Contractility Modulation (CCM) technology, and delivers non-excitatory electric pulses. The Optimizer is CE is FDA approved.
- Dec 2025Series F$158M
- Feb 2025Unattributed$84.1M
- Feb 2024Series E$136.5M
- Jul 2023Series E$91.4M
#2
Series D · Berkeley Heights, New Jersey · founded 2019$287Mraised▾
Developer of therapies for patients with cardiometabolic conditions. It offers a pipeline of treatments including an oral small molecule GLP-1 receptor agonist for the treatment of obesity and diabetes mellitus, JX10 is an investigational drug for acute ischemic stroke, and JX09 a next-generation highly selective aldosterone synthase inhibitor for hypertension, heart failure and chronic kidney disease.
- Jan 2026Series D$287M
#3
Seed · Montclair, New Jersey · founded 2016 · 4 employees$2.2Mraised▾
CorFigo is a developer of a HeArTPAD (Helium-Argon Trans-Pericardial Ablation Device) for the treatment of cardiac disorders. The HeArTPAD device is placed adjacent to the heart which ablates the atrial tissue in the heart. The device is inflated after its placement to enable the ablation surface to come in contact with the tissue and ultra-cold Argon gas is sent via the ablating surface for cryoadhesion to ablate the tissue in contact. Helium gas is sent to the device to thaw the cryoadhesion of the device with the tissue enabling the removal of the device.
- Dec 2025Seed$2.4M
- Jun 2023Seed$175K
- Jul 2019Seed$2.2M
- Mar 2017Seed$1.2M
#4
Series C · Cresskill, New Jersey · founded 2001 · 9 employees$103.9Mraised▾
Biotechnology firm improving vascular access by reducing surgical stenosis. The company focuses on developing solutions for patients with kidney and vascular disease. Their investigational product is a sirolimus formulation for local drug delivery, designed to prevent narrowing and ensure blood flow for hemodialysis patients. This innovative approach aims to improve patient outcomes, reduce catheter dependence, and enhance the success of arteriovenous fistulas. The company's work has a social impact by addressing a major problem in hemodialysis access, potentially benefiting patients, healthcare providers, and payors. They are involved in clinical trials to determine the safety and effectiveness of their product.
- Mar 2022Series C$25M
- Jan 2020Series B$17.3M
- Nov 2019Conventional Debt$7.4M
- Oct 2018Series B$12.4M
#5
Deadpooled · New Providence, New Jersey · founded 2007 · 3 employees$133.3Mraised▾
Developer of drug-eluting coronary stents. The key product is SLENDER IDS, a drug-eluting stent-on-a-wire integrated system. SLENDER IDS is CE Marked. Other products include a Direct rapid exchange system( DIRECT RX ) designed for direct and to promote healing.
- May 2021Series C$5.4M
- Nov 2017Series C$3M
- Jul 2017Series C$12.3M
- Jul 2016Series C$50.4M
#6
Series B · Short Hills, New Jersey · founded 2010 · 6 employees$17.8Mraised▾
Developer of therapy to reverse coronary atherosclerosis. The PDS-2 System is a therapeutic device that uses patient's own plasma to create natural pre-β HDL and efficiently reduce plaques which reduces the risk of cardiovascular disorders.
- Jul 2023Series B$1.3M
- Mar 2021Series B$3.4M
- Oct 2019Series B$3M
- May 2017Series B$7.2M
#7
Acqui-Hired · Wayne, New Jersey · founded 2011 · 64 employees$123.4Mraised▾
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products, focused on treating peripheral artery disease. The Tack Endovascular System repairs arterial dissections following angioplasty using a metal implant. The device received the CE mark and is FDA approved.
- Jul 2020Venture Debt$30M
- May 2020Series D$13.5M
- May 2019Series D$25M
- Apr 2018Series C$20M
#8
Acqui-Hired · Teaneck, New Jersey · founded 2004 · 13 employees$99Mraised▾
CircuLite is a developer of cardiac implants for early-stage heart failure patients. It has developed a cardiovascular device that is minimally-invasive micro-pumps for long-term partial circulatory support (PCS). The company’s proprietary micro-pump platform enables its PCS devices to be so small that they can be implanted superficially in a pacemaker-like pocket with endovascular or minimally-invasive surgical techniques.
- Aug 2013Grant (prize money)$385.8K
- Jul 2013Grant (prize money)$492.3K
- Nov 2011Series D$30M
- Apr 2010Grant (prize money)$3.8M
#9
Acquired · Monmouth Junction, New Jersey · founded 1998 · 42 employees$70.8Mraised▾
TYRX Antibacterial Envelopes help stabilize Cardiac Implantable Devices (CIEDs) while also helping to reduce Surgical Site Infections (SSIs) such as Pacemaker Pocket Infection. The company was acquired by Medtronic in 2014.
- May 2013Series C$2M
- Jan 2013Series C$2M
- Feb 2012Series C$2.5M
- Dec 2010Conventional Debt$4M
#10
Series A · Princeton, New Jersey · founded 2007 · 37 employees$76Mraised▾
Innovating therapies for unmet medical needs in hypertension, cardiorenal, and infectious diseases. The company is a biotechnology research and development organization focused on providing innovative therapies. Their integrated discovery and development platform efficiently brings new drugs from bench to clinics. The science platform allows them to identify and progress products with significant differentiation, integrated with their compound library. They have established a strong pipeline of clinical and preclinical programs. The company is dedicated to research and development of novel solutions for hypertension, cardiorenal, and infectious diseases. They focus on novel therapies and innovative solutions for global health challenges.
- Jan 2018Series A$76M
- Series A$76M
#11
Deadpooled · Barnegat Light, New Jersey · founded 2005$6.2Mraised▾
Vasade Biosciences is developing inhibitors of 5-adenylyl cyclase (AC5) for cardioprotection against myocardial infarction and congestive heart failure. Inhibition of AC5 increases longevity protects against oxidative stress, osteoporosis and cardiac myopathies, increases physical stamina and decreases total body fat.
- Dec 2022Grant (prize money)$252.1K
- Sep 2018Grant (prize money)$1.5M
- Sep 2012Grant (prize money)$167.9K
- Apr 2012Grant (prize money)$1.8M
#12
Public · Hampton, New Jersey · founded 2014 · 18 employees$46.4Mraised▾
Bellerophon Therapeutics is a clinical-stage biotherapeutics company developing products to treat cardiopulmonary and cardiac diseases. Its product, the INOpulse is a combination drug-device therapy that they are developing for the treatment of pulmonary arterial hypertension (PAH), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF). The device delivers Nitrous Oxide, a vasodilator into the pulmonary blood vessels, thus dilating them. The company spun out from Ikaria in 2014. Its key products include a nitric oxide delivery device and a bio-absorbable cardiac matrix. Both products are still in development. The company went public in Feb 2015.
- Oct 2017Post IPO$23.4M
- Sep 2017Post IPO$23M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.